

Joseph L Kuti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4532858/publications.pdf>

Version: 2024-02-01

146
papers

4,522
citations

117625

34
h-index

118850

62
g-index

148
all docs

148
docs citations

148
times ranked

3610
citing authors

#	ARTICLE	IF	CITATIONS
1	A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?. <i>Journal of Pharmacy Practice</i> , 2023, 36, 537-541.	1.0	2
2	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. <i>Hospital Pharmacy</i> , 2022, 57, 496-503.	1.0	2
3	<i>In Vitro</i> Time-Kill Studies of Trimethoprim/Sulfamethoxazole against <i>Stenotrophomonas maltophilia</i> versus <i>Escherichia coli</i> Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0216721.	3.2	6
4	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1052-1060.	3.0	12
5	Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using <i>in vivo</i> microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	5
6	Infection and Antibiotic Agents in Bleeding Trauma Patients: A Review of Available Literature. <i>Surgical Infections</i> , 2022, 23, 332-338.	1.4	1
7	Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man. <i>Frontiers in Pharmacology</i> , 2022, 13, 833189.	3.5	24
8	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106603.	2.5	7
9	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against <i>Pseudomonas aeruginosa</i> from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 9.	3.8	9
10	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021, 41, 220-233.	2.6	61
11	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106299.	2.5	23
12	Levofloxacin pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 164-168.	3.0	12
13	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial <i>Stenotrophomonas maltophilia</i> bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106395.	2.5	12
14	Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. <i>Surgical Infections</i> , 2021, , .	1.4	0
15	1103. Minocycline (MIN) Pharmacodynamics (PD) against <i>Stenotrophomonas maltophilia</i> (STM) in a Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2021, 8, S643-S643.	0.9	1
16	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>Open Forum Infectious Diseases</i> , 2021, 8, S646-S646.	0.9	2
17	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S147-S148.	0.9	0
18	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021, 8, S635-S635.	0.9	1

#	ARTICLE	IF	CITATIONS
19	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against <i>Stenotrophomonas maltophilia</i> (STM). <i>Open Forum Infectious Diseases</i> , 2021, 8, S44-S44.	0.9	0
20	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020, 70, 1240-1246.	5.8	29
21	Monte Carlo Simulation Methodologies for β -Lactam/ β -Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 172-180.	2.0	8
22	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
23	Imipenem/Cilastatin/Relebactam Alone and in Combination against <i>Pseudomonas aeruginosa</i> in the <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	8
24	Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 482-494.	3.1	14
25	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020, 42, 606-613.	2.5	9
26	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1546-1553.	3.0	43
27	Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 705-720.	4.4	14
28	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020, 7, S667-S667.	0.9	0
29	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against <i>Pseudomonas Aeruginosa</i> (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020, 7, S7-S8.	0.9	0
30	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against <i>Pseudomonas aeruginosa</i> (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020, 7, S797-S797.	0.9	0
31	112. Impact of Respiratory Viral PCR Panels (RVP) and Serum Procalcitonin (PCT) on Antibiotic Days of Therapy (DOT) in Patients Admitted with Lower Respiratory Tract Infections (LRTI). <i>Open Forum Infectious Diseases</i> , 2020, 7, S70-S70.	0.9	0
32	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against <i>Pseudomonas aeruginosa</i> (PSA) in the <i>In Vitro</i> Pharmacodynamic Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S667-S667.	0.9	0
33	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020, 7, S670-S670.	0.9	1
34	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	6
35	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β -Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	5
36	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019, 41, 1453-1462.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019, 8, 383-396.	4.0	14
38	<i>In Vitro</i> Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	24
39	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 346-350.	2.5	9
40	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019, 41, 2162-2170.	2.5	8
41	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 444-445.	1.0	0
42	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	6
43	Carbapenem-Nonsusceptible <i>Pseudomonas aeruginosa</i> Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	29
44	<i>In Vitro</i> Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	8
45	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 698-702.	2.5	3
46	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019, 69, 903-904.	5.8	1
47	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	5
48	888. <i>Critical Care Medicine</i> , 2019, 47, 423.	0.9	1
49	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019, 68, 1650-1657.	5.8	42
50	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019, 20, 55-61.	1.4	37
51	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	5
52	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
53	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 294-297.	1.8	16
54	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 397-408.	1.8	24

#	ARTICLE	IF	CITATIONS
55	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018, 40, 261-269.	2.5	16
56	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via <i>In Vivo</i> Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
57	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018, 18, 932.	2.2	11
58	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy206.	0.9	4
59	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). <i>Open Forum Infectious Diseases</i> , 2018, 5, S47-S47.	0.9	0
60	1398. $\hat{\beta}$ -Lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) Based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2018, 5, S430-S430.	0.9	0
61	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, e36-e44.	1.0	12
62	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1048-1056.	1.0	15
63	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
64	Defining the potency of amikacin against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 783-790.	2.7	17
65	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 712-719.	2.0	22
66	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e55-e63.	1.0	3
67	Effects of Clinically Meaningful Concentrations of Antipseudomonal $\hat{\beta}$ -Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3502-3512.	3.9	6
68	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
69	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017, 30, 593-599.	1.0	6
70	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a "Goldilocks" window. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 487-490.	2.5	21
71	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 617-633.	3.5	47
72	Simplifying Piperacillin/Tazobactam (TZP) Dosing: Pharmacodynamics (PD) of Utilizing 4.5g Doses for Patients With Normal and Impaired Renal Function. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0

#	ARTICLE	IF	CITATIONS
73	Prevalence and Risk Factors of a Novel Piperacillin/Tazobactam-Nonsusceptible, β -Lactam-Pan-Susceptible (TZP-NS/BL-PS) Phenotype in Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
74	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 215-218.	1.8	26
75	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 583-589.	1.8	27
76	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> : Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 955-961.	3.2	5
77	C�MO OPTIMIZAR LA FARMACODINAMIA ANTIMICROBIANA: UNA GU�A PARA UN PROGRAMA DE OPTIMIZACI�N DEL USO DE ANTIMICROBIANOS. <i>Revista M�dica Cl�nica Las Condes</i> , 2016, 27, 625-635.	0.2	0
78	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6578-6584.	3.2	35
79	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 342-343.	2.5	35
80	Continuous and Prolonged Intravenous β -Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016, 29, 759-772.	13.6	51
81	The Essential Role of Pharmacists in Antimicrobial Stewardship. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 753-754.	1.8	45
82	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1401-1410.	3.2	51
83	<i>In Vitro</i> Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 222-228.	3.2	3
84	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 247-248.	2.5	4
85	An exploratory analysis of the ability of a cefepime trough concentration greater than 22�mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 78-83.	1.7	31
86	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 459-476.	3.1	22
87	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 189-195.	3.0	25
88	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 256-9.	0.1	1
89	Mortality, Hospital Costs, Payments, and Readmissions Associated With <i>Clostridium difficile</i> Infection Among Medicare Beneficiaries. <i>Infectious Diseases in Clinical Practice</i> , 2015, 23, 318-323.	0.3	21
90	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 512-518.	2.5	9

#	ARTICLE	IF	CITATIONS
91	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 53-55.	1.8	34
92	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2064-2067.	3.0	20
93	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014, 3, 269-279.	4.0	16
94	<i>In Vitro</i> Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 672-677.	3.2	18
95	Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1359-1364.	3.2	68
96	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and ~20 °C. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1480-1484.	1.0	6
97	Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young Children. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 168-173.	2.0	64
98	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509.	9.1	745
99	Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes. <i>Clinical Infectious Diseases</i> , 2014, 59, 905-907.	5.8	28
100	Prolonging β -lactam infusion: A review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 105-113.	2.5	75
101	<i>In Vitro</i> Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 874-879.	3.2	65
102	<i>In Vitro</i> Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7520-7526.	3.2	17
103	Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5 Minute Infusion versus the Standard 30 Minute Infusion in Healthy Adult Volunteers. <i>Pharmacotherapy</i> , 2013, 33, 266-274.	2.6	32
104	<i>In Vitro</i> Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 202-207.	3.2	58
105	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011, 37, 632-638.	8.2	90
106	Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 2265-2270.	1.0	11
107	Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. <i>Journal of Critical Care</i> , 2010, 25, 69-77.	2.2	79
108	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – A review of 3 cases. <i>Respiratory Medicine CME</i> , 2010, 3, 146-149.	0.1	13

#	ARTICLE	IF	CITATIONS
109	Length of Stay and Hospital Costs Associated with a Pharmacodynamic-Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator-Associated Pneumonia. <i>Pharmacotherapy</i> , 2010, 30, 453-462.	2.6	27
110	Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> with a Range of Vancomycin MICs in a Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5115-5119.	3.2	53
111	Clinical Pharmacodynamics of Cefepime in Patients Infected with <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1111-1116.	3.2	110
112	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2062.	0.1	0
113	Tackling Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia in Your ICU: Guidance for Implementing the Guidelines. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 102-115.	2.1	19
114	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1476-1481.	3.2	114
115	Optimizing bactericidal exposure for β -lactams using prolonged and continuous infusions in the pediatric population. <i>Pediatric Blood and Cancer</i> , 2009, 53, 379-385.	1.5	70
116	Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant <i>Staphylococcus aureus</i> isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. <i>Connecticut Medicine</i> , 2009, 73, 337-40.	0.2	2
117	Influence of automated screening and confirmation of extended-spectrum β -lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. <i>Journal of Medical Microbiology</i> , 2008, 57, 1147-1151.	1.8	0
118	Pharmacodynamic Performance of Tigecycline versus Common Intravenous Antibiotics for the Empiric Treatment of Complicated Skin and Skin Structure Infections. <i>Surgical Infections</i> , 2008, 9, 57-66.	1.4	7
119	Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1725-1730.	3.2	254
120	Treatment of <i>Serratia marcescens</i> Meningitis with Prolonged Infusion of Meropenem. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1077-1081.	1.9	21
121	Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007, 29, 889-899.	2.5	12
122	Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 337-344.	1.8	54
123	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 452-457.	2.5	28
124	Optimal Dosing of Piperacillin-Tazobactam for the Treatment of <i>Pseudomonas aeruginosa</i> Infections: Prolonged or Continuous Infusion?. <i>Pharmacotherapy</i> , 2007, 27, 1490-1497.	2.6	71
125	Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles. <i>Drugs</i> , 2006, 66, 1-14.	10.9	85
126	Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 62-68.	2.5	26

#	ARTICLE	IF	CITATIONS
127	Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 69-75.	2.0	46
128	Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem. <i>Pharmacotherapy</i> , 2005, 25, 935-941.	2.6	25
129	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 388-395.	3.0	98
130	Derivation of Meropenem Dosage in Patients Receiving Continuous Veno-Venous Hemofiltration Based on Pharmacodynamic Target Attainment. <i>Chemotherapy</i> , 2005, 51, 211-216.	1.6	12
131	Use of Monte Carlo simulation to assess the pharmacodynamics of β -lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program. <i>Clinical Therapeutics</i> , 2005, 27, 1820-1830.	2.5	30
132	Making the most of surveillance studies: summary of the OPTAMA Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 281-287.	1.8	34
133	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004, 39, 1069-1075.	1.0	1
134	Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. <i>Pharmacotherapy</i> , 2004, 24, 8-15.	2.6	32
135	Empiric Treatment of Multidrug-Resistant Burkholderia cepacia Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy. <i>Pharmacotherapy</i> , 2004, 24, 1641-1645.	2.6	35
136	Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2464-2470.	3.2	96
137	Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections. <i>Pharmacoeconomics</i> , 2004, 22, 301-310.	3.3	20
138	Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. <i>Clinical Therapeutics</i> , 2004, 26, 1187-1198.	2.5	101
139	Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis*1. <i>Clinical Therapeutics</i> , 2004, 26, 493-501.	2.5	77
140	Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1116-1123.	2.0	169
141	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 565-568.	1.0	36
142	Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. <i>Connecticut Medicine</i> , 2003, 67, 85-8.	0.2	0
143	Cefditoren Pivoxil. <i>Drugs</i> , 2002, 62, 337-338.	10.9	1
144	Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance. <i>Pharmacoeconomics</i> , 2002, 20, 513-528.	3.3	28

#	ARTICLE	IF	CITATIONS
145	Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> using Monte Carlo analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 51-57.	1.8	36
146	Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 2209-2215.	1.0	54